Stanford is honored to have several presenters and to have contributed to more than 40 oral and poster abstracts at the 2025 Transplantation & Cellular Therapy Meetings for the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood Marrow Transplantation Research (CIBMTR). We've listed all presentations featuring a Stanford speaker below.

Oral abstract and session presenters

Poster presentations

Cameron Bader, MD
Persistence of Alloreactive T Regulatory Cell Clones Correlates With Mixed Chimerism After Combined Kidney and Hematopoietic Cell Transplantation

Chaiyaporn Boonchalermvichian, MD, PhD
Engineered Invariant Natural Killer T Cells (iNKT cells) Targeting CD 117 As a Novel Treatment for Acute Myeloid Leukemia

Pin-I Chen, PhD
Targeting Monocytes with Human Folate Receptor β Chimeric Antigen Receptor (CAR)-CD39+ Treg Subset Improves Immune Regulatory Function of the Monocytes That May Restore Tolerance in Autoimmune Diseases

Tara Coghlin Dickson, MS, RD, CSSD, FAND
Exploring Vitamin D Monitoring and Supplementation Strategies in HCT Patients at an Academic Medical Center

Anmol Goyal, MD
Impact of Obesity on Efficacy, Safety, and Expansion Kinetics of Chimeric Antigen Receptor T-Cell (CAR T) Therapy in Relapsed or Refractory Large B-Cell Lymphoma

Biki Gupta, PhD
Host-Derived Immunoregulatory Invariant Natural Killer T Cell Subset, iNKT2 Is Instrumental for Prevention of Acute Graft Versus Host Disease in Mice

Sylvester Homsy, MD
Point-of-Care Bispectral Electroencephalogram (BSEEG) As a New Tool in Detecting Immune Effector Cell Associated Neurotoxicity (ICANS) in Patients Treated With Chimeric Antigen Receptor T-Cell (CAR-T)

Kayla Jenkins
Proinflammatory Mediators Leading to Graft Transition Syndrome in the Context of Living Donor Kidney Transplantation

Inna Kaplan, DNP, RN, OCN, CNL
Beyond Treatment: Empowering Recovery and Promoting Long-Term Health With Personalized Survivorship Care Plans (SCP) in Hematopoietic Stem Cell Transplant (HCT) Recipients

Vanessa Kennedy, MD
Comparison of Post-Transplant Cyclophosphamide Vs Methotrexate and Calcineurin Inhibitor for Gvhd Prophylaxis in Myeloablative Transplants With HLA Matched Donors

Yong Bin "Phil" Kim, BS
Next Generation Immune Tolerance Conditioning: Anti-CD3 T Cell Depletion With OrthoCD3 Shielding of Regulatory T Cells

Everett Meyer, MD
Observational Comparison of Overall Survival Between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

David B. Miklos, MD, PhD
Rapid Increase in Blood CD19 CAR-T Vector Load During the First 5 Days Post Infusion Is Associated With Severe Icans

Thomas Orozco
Challenges and Efficient Management of Cryopreserved Cell Product Inventory

Shiva Pathak, PhD
Regulatory T Cell-Mediated Selective Deletion of Islet ß Antigen-Specific Autoreactive T Cells in Type 1 Diabetes

Masooma Shifa Rana, MD
Dynamics of B Cell Maturation Antigen (BCMA) Expression Pre-Treatment and at Relapse in Patients With Relapsed/Refractory Multiple Myeloma Receiving BCMA Directed CAR-T Cell Therapy

Chandan Sanghera, MBBS
Development of a Circulating Free DNA (cfDNA) Assay for the Detection of Measurable Residual Disease to Predict Relapse in Patients With B-Cell Acute Lymphoblastic Leukemia

Gabriel E Seir, BS
Single-Cell and Bulk RNA Sequencing Analysis of Adult Patients With Acute Myeloid Leukemia to Identify Potential for Transferability of Pediatric Trivalent CAR-T Approaches

Surbhi Sidana, MD
Ciltacabtagene Vicluecel (Cilta-cel) Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM) With Renal Impairment: Real World Experience

Hrishikesh K. Srinagesh, MD, MSCR
CD22-Directed CAR T-Cell Therapy Achieves Complete Remission in CD19-Directed CAR T-Cell Refractory Follicular and Mantle Cell Lymphoma With Superior Safety and Absence of Neurotoxicity

Dilek Uzun, MD
The Impact of Anti-CD38-Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Real-World Data 2021-2023

Alejandro Villar-Prados, MD, PhD
Phase 1 Trial Results for Patients With Advanced Hematologic Malignancies Treated With Allogeneic T Cell Immunotherapy and Reduced Intensity Conditioning

William Lee Wang, BA
Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and Icans

Hao Yan, PhD
CD117 CAR-iNKT Cells As a Safe and Effective Off-the-Shelf Allogeneic Cell Therapy for AML